The U.S. Food and Drug Administration (FDA) will now restrict COVID-19 vaccine approvals primarily to high-risk groups (65+, immunocompromised and those with underlying conditions). Manufacturers must prove effectiveness in preventing severe outcomes (hospitalization/death) for healthy individuals …